An official website of the United States government Here’s how you know

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

In this section: Vaccines, Blood & Biologics

AREXVY

STN: 125775
Proper Name: Respiratory Syncytial Virus Vaccine, Adjuvanted
Tradename: AREXVY
Manufacturer: GlaxoSmithKline Biologicals SA
Indication:

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:
- Individuals 60 years of age and older;
- Individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV

Product Information

Package Insert - AREXVY
Demographic Subgroup Information – Respiratory Syncytial Virus Vaccine, Adjuvanted (AREXVY)
Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

Top